# A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

> **NCT03871348** · PHASE1 · TERMINATED · sponsor: **Sanofi** · enrollment: 77 (actual)

## Conditions studied

- Metastatic Neoplasm

## Interventions

- **DRUG:** SAR441000
- **DRUG:** Cemiplimab REGN2810

## Key facts

- **NCT ID:** NCT03871348
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-01-03
- **Primary completion:** 2022-07-25
- **Final completion:** 2024-02-21
- **Target enrollment:** 77 (ACTUAL)
- **Why stopped:** Sponsor terminated the study for non-safety reasons
- **Last updated:** 2025-09-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03871348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03871348, "A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT03871348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*